Rare Pediatric Disease Priority Review Voucher

RNA Concept 3D Render

Biotech

RNA biotech emerges with $52M and clinical rare disease asset

Arnatar currently touts seven assets, with six preclinical programs that range across cardiometabolic, inflammatory and CNS conditions.

Gabrielle Masson Aug 25, 2025 10:13am

Man hands gold dollar sign to another man

Fierce Pharma

Bavarian Nordic's $160M PRV price reflects new realities

Jun 18, 2025 11:47am

Money in the hands of businessmen with contract signing

PTC sells priority review voucher from Kebilidi nod for $150M

Nov 27, 2024 8:35am

money funding financing bank

Acadia makes $100M profit from $150M pediatric voucher sale

Nov 6, 2024 9:36am

curtains spotlight show performance

AAV gene therapy biotech unveils with 10 pipeline products

Sep 12, 2024 7:00am

paper arrows upgrade upwards path

BridgeBio adds another $110M to coffers with voucher sale

May 13, 2022 9:45am